Monday, December 29, 2025 | 01:55 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Page 20 - Pharma Companies

3 firms get clinical trial approval for alternative Covid-19 drugs

The drug 2-DG is not yet an approved drug, but there have been multiple studies across the globe for treatment of cancers

3 firms get clinical trial approval for alternative Covid-19 drugs
Updated On : 16 Oct 2020 | 6:05 AM IST

Smaller pharma firms post faster domestic sales growth in September

Barring Cipla and Glenmark, whose sales have grown in double digits due to demand for their Covid-19 drugs like favipiravir, tocilizumab, most big players have posted tepid growth

Smaller pharma firms post faster domestic sales growth in September
Updated On : 12 Oct 2020 | 10:47 PM IST

PE/VC investments in pharma companies grow 3.5X in 2020, cross $1 bn mark

The reputation and relationships have helped pharma industry raise huge amounts of PE capital in 2020.

PE/VC investments in pharma companies grow 3.5X in 2020, cross $1 bn mark
Updated On : 06 Oct 2020 | 1:10 AM IST

Patented molecules clock a high growth rate in Indian cardiovascular market

In January 2020, the Delhi High Court granted an injunction restraining domestic companies such as Cipla, Torrent, Emcure, and Alkem from launching their brands

Patented molecules clock a high growth rate in Indian cardiovascular market
Updated On : 03 Oct 2020 | 6:05 AM IST

Revised, more industry-friendly PLI scheme for bulk drugs on the cards

Industry says move will mean lower spends and reduced dependence on China

Revised, more industry-friendly PLI scheme for bulk drugs on the cards
Updated On : 02 Oct 2020 | 6:05 AM IST

Credit metrics of leading pharma companies to remain stable: ICRA

The global demand scenario for Indian pharmaceutical industry is largely expected to remain stable due to inelastic nature of prescription drugs, investment information agency ICRA has said.

Image
Updated On : 26 Sep 2020 | 2:19 PM IST

Syngene: Investors with long term view should look at the stock on dips

While Covid-19 could is a near term opportunity, contract manufacturing is the key medium-term trigger

Syngene: Investors with long term view should look at the stock on dips
Updated On : 25 Sep 2020 | 1:17 AM IST

Lupin launches generic Divalproex Sodium tablets for bipolar disorder in US

According to IQVIA MAT July 2020 data, Divalproex Sodium extended-release tablets USP had annual sales of approximately USD 130 million (about Rs 950 crore) in the US

Lupin launches generic Divalproex Sodium tablets for bipolar disorder in US
Updated On : 22 Sep 2020 | 6:55 PM IST

Gilead nears deal to buy Immunomedics for more than $20 billion: Report

Discussions between Gilead and Immunomedics were initially centered around a partnership before shifting to a full-fledged takeover negotiation

Gilead nears deal to buy Immunomedics for more than $20 billion: Report
Updated On : 13 Sep 2020 | 8:25 AM IST

Gilead nears deal to buy Immunomedics for more than $20 bn: WSJ report

Gilead Sciences Inc is said to be nearing a deal to buy biopharmaceutical company Immunomedics Incfor more than $20 billion in a deal that would further expand Gilead's portfolio of cancer treatments

Gilead nears deal to buy Immunomedics for more than $20 bn: WSJ report
Updated On : 13 Sep 2020 | 3:20 AM IST

BPPI Q1 sales turnover up 94.21% to Rs 146.59 cr amid Covid-19 crisis

It had posted a sales turnover of Rs 75.48 crore in the corresponding first quarter of previous fiscal year, a statement by the ministry said

BPPI Q1 sales turnover up 94.21% to Rs 146.59 cr amid Covid-19 crisis
Updated On : 06 Sep 2020 | 7:56 PM IST

Remdesivir prices may rise after Gilead gets full authorisation from USFDA

In August, Gilead filed an application with the US Food and Drug Administration (USFDA) seeking full approval for remdesivir (Veklury)

Remdesivir prices may rise after Gilead gets full authorisation from USFDA
Updated On : 04 Sep 2020 | 10:49 PM IST

Pick-up in biosimilar launches driving Biocon's prospects; stock rises 7.8%

As US launch of Insulin addresses a large market, improved visibility for more launches will keep sentiment elevated

Pick-up in biosimilar launches driving Biocon's prospects; stock rises 7.8%
Updated On : 02 Sep 2020 | 3:14 AM IST

Pharmacy consolidation may disrupt domestic drug market: Credit Suisse

The report says if chemists are allowed to replace doctor's prescription with a generic drug, firms with high exposure to chronic therapeutic drugs will be impacted more

Pharmacy consolidation may disrupt domestic drug market: Credit Suisse
Updated On : 25 Aug 2020 | 11:51 PM IST

National Expert Group meets Covid-19 vaccine makers to discuss road ahead

Representatives from Serum Institute of India, Bharat Biotech, Zydus Cadila, Gennova Biopharmaceuticals and Biological E met the expert group that is chaired by NITI member Vinod K Paul

National Expert Group meets Covid-19 vaccine makers to discuss road ahead
Updated On : 18 Aug 2020 | 1:42 AM IST

France's Sanofi SA to buy US-based Principia Biopharma for $3.7 billion

The deal will strengthen Sanofi's research capabilities in areas such as autoimmune and allergic diseases, the companies said

France's Sanofi SA to buy US-based Principia Biopharma for $3.7 billion
Updated On : 18 Aug 2020 | 12:59 AM IST

Natco Pharma reports 14.5% decline in net profit at Rs 122 cr for Q1

The company had posted a net profit of Rs 142.8 crore for the corresponding period of the previous fiscal

Natco Pharma reports 14.5% decline in net profit at Rs 122 cr for Q1
Updated On : 12 Aug 2020 | 5:22 PM IST

Pharma rally may lose steam as valuations factor in near term gains

Recovery in India business, traction in new launches in the US market are needed to sustain gains

Pharma rally may lose steam as valuations factor in near term gains
Updated On : 11 Aug 2020 | 9:47 PM IST

Mankind Pharma partners with South Korea's Daewoong for Covid drug

Will conduct clincial trials on anti-parasitic drug they claim is more effective than remdesivir

Mankind Pharma partners with South Korea's Daewoong for Covid drug
Updated On : 11 Aug 2020 | 5:57 PM IST

Ipca Labs Q1 profit jumps more than 3-folds to Rs 445.68 cr on robust sales

The company had posted a net profit of Rs 129.43 crore for the corresponding period of the previous fiscal, Ipca Labs said in a BSE filing

Ipca Labs Q1 profit jumps more than 3-folds to Rs 445.68 cr on robust sales
Updated On : 10 Aug 2020 | 7:36 PM IST